Lack of Consensus for Margin Width Leads to Additional Breast Cancer Surgery
the Cancer Therapy Advisor take:
According to researchers from the University of Wisconsin School of Medicine and Public Health, the lack of consensus or established guidelines on the sufficient distance of excision between the tumor and the edge of surrounding tissue during breast cancer surgery has lead to variable excision rates and additional operations, by as much as 60%.
The authors of a study published recently in JAMA Surgery used the National Cancer database to analyze data from 316,114 patients who underwent breast cancer surgery in the United States between 2004 and 2010 (patients who were initially treated with chemotherapy or excision biopsy were excluded).
Seventy-six percent of these patients had a single lumpectomy, and of those patients, almost 24% had at least one additional operation for their breast cancer (62% with a completion lumpectomy; 38% with a complete mastectomy). It is hoped that the results from this analysis will help to inform patients about the risk for repeat surgery for breast cancer, and will also spur guidelines that will standardize tumor margin and help reduce local recurrence rates.
Additional breast cancer operations can cause the patient added distress, cost, and delays to adjuvant therapy, so avoiding these often unnecessary surgeries may ultimately improve patient outcome and prevent wasted health care resources.
Lack of consensus on distance of excision between tumor and tissue has lead to variable excision rates.
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|
|Renal Cell Carcinoma||Regimens||Drugs|
Cancer Therapy Advisor Articles
- Plastics and Cancer
- Real-World Study Shows High Response Rates to T-VEC in Early Metastatic Melanoma
- Using ctDNA to Predict Cancer Recurrence and Guide Therapy Selection
- Cabozantinib Shows Promising Activity in Osteosarcoma and Ewing Sarcoma
- Are Next-Gen Antibody-Drug Conjugates a Path Forward for Non-Hodgkin Lymphoma and Myeloma?
- First-Line Alectinib Effective in Asian Patients With ALK-Positive Advanced NSCLC
- Pembrolizumab Alone or With Chemotherapy Prolongs OS in Recurrent/Metastatic HNSCC
- Pembrolizumab With Dabrafenib and Trametinib Shows Efficacy, But High TRAEs, in Melanoma
- Assays May Help Researchers Discover Factors Underlying Immunotherapy Response
- Atezolizumab Combo Improved PFS, OS in Stage IV Non-Small Cell Lung Cancer